Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML - PubMed (original) (raw)
Clinical Trial
. 2009 Sep 10;114(11):2220-31.
doi: 10.1182/blood-2009-03-213389. Epub 2009 Jul 8.
Affiliations
- PMID: 19587375
- DOI: 10.1182/blood-2009-03-213389
Free article
Clinical Trial
Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML
Susanne Schnittger et al. Blood. 2009.
Free article
Abstract
Nucleophosmin (NPM1)-mutated acute myeloid leukemia (AML), which is recognized as a provisional entity in the World Health Organization 2008 classification of myeloid neoplasms, accounts for 30% of AML. We analyzed 1227 diagnostic and follow-up samples in 252 NPM1-mutated AML patients with 17 different NPM1 mutation-specific real-time quantitative polymerase chain reaction (RQ-PCR) assays. Paired diagnostic/relapse samples of 84 patients revealed stable NPM1 mutations in all cases, suggesting that they are pathogenetically early events and thus applicable for minimal residual disease detection. A total of 47 relapses were predictable because of an NPM1 mutation level (%NPM1/ABL1) increase of at least 1 log or in 15 cases because of NPM1 mutation levels not decreasing less than 3 log ranges. A high prognostic value of NPM1 levels was shown for 4 different intervals after therapy was initiated. Furthermore, thresholds of 0.1 and 0.01%NPM1/ABL1 during/after treatment discriminated between prognostic subgroups. Univariate analyses, including age, white blood cell count, blast count, CD34 positivity, FLT3 mutations status, FAB type, karyotype, NPM1 mutation type, and pretreatment NPM1 mutational level, showed that, besides NPM1 mutation level, only age and FLT3-LM mutation status were prognostically significant for EFS. Multivariate analysis, including age, FLT3-LM status, and NPM1 mutation level at different time points, demonstrated that NPM1 level was the most relevant prognostic factor during first-line treatment. Similar results were obtained in patients undergoing second-line chemotherapy or allogeneic stem cell transplantation.
Similar articles
- CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H, Chen Y, Kamel-Reid S, Brandwein J, Chang H. Dang H, et al. Hum Pathol. 2013 Oct;44(10):2038-46. doi: 10.1016/j.humpath.2013.03.007. Epub 2013 May 21. Hum Pathol. 2013. PMID: 23701943 - FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
Rezaei N, Arandi N, Valibeigi B, Haghpanah S, Khansalar M, Ramzi M. Rezaei N, et al. Turk J Haematol. 2017 Dec 1;34(4):300-306. doi: 10.4274/tjh.2016.0489. Epub 2017 Mar 15. Turk J Haematol. 2017. PMID: 28294102 Free PMC article. - The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML.
Shayegi N, Kramer M, Bornhäuser M, Schaich M, Schetelig J, Platzbecker U, Röllig C, Heiderich C, Landt O, Ehninger G, Thiede C; Study Alliance Leukemia (SAL). Shayegi N, et al. Blood. 2013 Jul 4;122(1):83-92. doi: 10.1182/blood-2012-10-461749. Epub 2013 May 8. Blood. 2013. PMID: 23656730 - Minimal/Measurable Residual Disease Monitoring in _NPM1_-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives.
Forghieri F, Comoli P, Marasca R, Potenza L, Luppi M. Forghieri F, et al. Int J Mol Sci. 2018 Nov 6;19(11):3492. doi: 10.3390/ijms19113492. Int J Mol Sci. 2018. PMID: 30404199 Free PMC article. Review. - Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.
Port M, Böttcher M, Thol F, Ganser A, Schlenk R, Wasem J, Neumann A, Pouryamout L. Port M, et al. Ann Hematol. 2014 Aug;93(8):1279-86. doi: 10.1007/s00277-014-2072-6. Epub 2014 May 7. Ann Hematol. 2014. PMID: 24801015 Review.
Cited by
- Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.
Christopher MR, Nawas MT, Reagan JL. Christopher MR, et al. Bone Marrow Transplant. 2024 Nov 13. doi: 10.1038/s41409-024-02465-2. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 39537780 Review. - Detection methods and prognosis implications of measurable residual disease in acute myeloid leukemia.
Zhao Z, Lan J. Zhao Z, et al. Ann Hematol. 2024 Sep 16. doi: 10.1007/s00277-024-06008-z. Online ahead of print. Ann Hematol. 2024. PMID: 39283479 Review. - Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study.
Orvain C, Bertoli S, Peterlin P, Desbrosses Y, Dumas PY, Iat A, Hospital MA, Carre M, Tavernier E, Riou J, Bouvier A, Bidet A, Tondeur S, Renosi F, Mozziconacci MJ, Flandrin-Gresta P, Dadone-Montaudié B, Delabesse E, Pigneux A, Hunault-Berger M, Recher C. Orvain C, et al. Leukemia. 2024 Sep;38(9):1949-1957. doi: 10.1038/s41375-024-02335-2. Epub 2024 Jul 17. Leukemia. 2024. PMID: 39020060 Free PMC article. - Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?
Rahmé R, Braun T. Rahmé R, et al. J Clin Med. 2024 Jan 18;13(2):549. doi: 10.3390/jcm13020549. J Clin Med. 2024. PMID: 38256681 Free PMC article. Review. - Allogeneic hematopoietic stem cell transplantation and pre-transplant strategies in patients with NPM1-mutated acute myeloid leukemia: a single center experience.
Jäger P, Rautenberg C, Kaivers J, Kasprzak A, Geyh S, Baermann BN, Haas R, Germing U, Schroeder T, Kobbe G. Jäger P, et al. Sci Rep. 2023 Jul 4;13(1):10774. doi: 10.1038/s41598-023-38037-5. Sci Rep. 2023. PMID: 37402862 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous